Skip to Content

Isavuconazonium Dosage

Medically reviewed by Drugs.com. Last updated on Jan 31, 2020.

Applies to the following strengths: 186 mg; 372 mg

Usual Adult Dose for Aspergillosis - Invasive

Loading Dose: 372 mg IV or orally every 8 hours for 6 doses (48 hours)
Maintenance Dose: 372 mg IV or orally once a day

Comments:
-Isavuconazonium sulfate is the prodrug of isavuconazole; 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole.
-Maintenance doses should be started 12 to 24 hours after the last loading dose.

Uses: For the treatment of invasive aspergillosis and invasive mucormycosis

Usual Adult Dose for Mucormycosis - Invasive

Loading Dose: 372 mg IV or orally every 8 hours for 6 doses (48 hours)
Maintenance Dose: 372 mg IV or orally once a day

Comments:
-Isavuconazonium sulfate is the prodrug of isavuconazole; 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole.
-Maintenance doses should be started 12 to 24 hours after the last loading dose.

Uses: For the treatment of invasive aspergillosis and invasive mucormycosis

Renal Dose Adjustments

Mild, moderate, or severe renal dysfunction: No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A and B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

Comments:
-This drug should be used in patients with severe liver dysfunction only if the benefits outweigh the risks.

Precautions

CONTRAINDICATIONS:
-Known hypersensitivity to the active component
-Coadministration with strong CYP450 3A4 inhibitors (e.g., ketoconazole, high-dose ritonavir [400 mg every 12 hours])
-Coadministration with strong CYP450 3A4 inducers (e.g., rifampin, carbamazepine, long-acting barbiturates, St. John's wort)
-Familial short QT syndrome

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

ESRD: No adjustment recommended.

Other Comments

Administration advice:
-Administer IV formulation via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron).
-Infuse the IV formulation over a minimum of 1 hour in 250 mL of compatible diluent (to reduce risk for infusion-related reactions); do not administer as IV bolus injection.
-Do not infuse with any other IV drugs.
-Flush IV lines with 0.9% sodium chloride injection, USP or 5% dextrose injection, USP before and after infusion.
-Avoid unnecessary vibration or vigorous shaking of the diluted IV solution; do not use a pneumatic transport system.
-May switch between IV and oral formulations (bioequivalent); no loading dose needed when switching between formulations.
-Swallow capsules whole; do not chew, crush, dissolve, or open capsules.
-Administer capsules with or without food.

Storage requirements:
-Capsules: Store at 20C to 25C (68F to 77F) in the original bottle to protect from moisture; excursion permitted to 15C to 30C (59F to 86F).
-IV (unreconstituted vials): Store at 2C to 8C (36F to 46F) in refrigerator.
-IV (reconstituted solution): Should use immediately; may be stored below 25C up to 1 hour before preparation of the patient infusion solution
-IV (diluted infusion solution): Complete infusion within 6 hours of dilution at room temperature (20C to 25C [68F to 77F]); if this is not possible, refrigerate (2C to 8C [36F to 46F]) the infusion solution immediately after dilution and complete infusion within 24 hours; do not freeze.

Reconstitution/preparation techniques:
-IV formulation requires reconstitution and then dilution before infusion; the manufacturer product information should be consulted.

IV compatibility:
-Compatible diluents: 0.9% sodium chloride injection, USP; 5% dextrose injection, USP

General:
-Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained before therapy to isolate and identify causative organisms; therapy may be started before results are known, but once available, antifungal therapy should be adjusted accordingly.

Monitoring:
-General: For drug-related side effects in patients with severe liver dysfunction
-Hepatic: Liver-related laboratory tests (at the start of and during therapy); for more severe hepatic injury in patients with abnormal liver-related laboratory tests (during therapy)

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information).

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.